Extubation following dacryocystorhinostomy: an alternative technique

Reply to: ‘Comment on: ‘One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration’

“…On the other hand, a proactive approach using Aflibercept as per VIEW showed good results in routine clinical practice across the UK 7 in addition to results comparable to VIEW as achieved in our cohort. 1 This trend of losing vision post loading when PRN regimen is applied can be observed in Figure 1 of your response; your VA results at M12 (3-4 ETDRS L gain) were inferior to both MARINA and ANCHOR, and inferior to what had already been achieved in the major VIEW 1&2 RCTs using Eylea 2 and inferior to what's been achieved in our cohort. 1 In our research, a total number of seven injections were given; a total of only three follow-up visits were booked per patient per year.…”

“…We believe that visual outcomes of our work are satisfactory; in the integrated analysis of the VIEW 1&2 RCTs, 2 the proportion maintaining vision (losing o15 ETDRS L) was 95% (94% in our cohort), whereas the proportion gaining 415 ETDRS L was 31% (24% in our cohort of the published work).…”

“…In case you used it monthly (Q4W), what would be the benefit of using Aflibercept every month if the current evidence suggested that its use bi-monthly (Q8W) was not inferior to monthly ranibizumab? 2 Once a patient commences anti-VEG therapy, maintaining post-loading gain is a clinical challenge. In your protocol, a REACTIVE regimen was adopted in inactive eyes post loading.…”

Simple fixation and removal of dacryocystorhinostomy tube

“…We read with great interest the DCR stent fixation and removal technique by Galea et al, 2 which involves insertion of a bicanalicular silicone tube tied with two 6/0 silk sutures, and removal by cutting the loop of the tube close to the lower punctum, followed by pulling the upper cut end of the tube laterally through the upper canaliculus to externalize the rest of the tube and sutures.…”